$TENX

5 theses

bullish 100%neutral 0%bearish 0%

Avg return (6m)

—

Win rate (6m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 1, 12:31 PM ET

$TENXr/pennystocksBullishbullish

u/Da1lyGa1ns · 39d ago3 prior · awaiting results

$TENX Cantor Fitzgerald Reiterates rating and $35 Price Target

Cantor Fitzgerald reiterates overweight rating with a $35 price target (1,695% upside from current $1.95), supported by positive HELP trial data showing safety, efficacy in reducing NT-proBNP by 49%, and a planned enriched LEVEL-2 trial. Insider buying from expert bio investor Dr. Schneeberger and strong analyst support suggest conviction in the biotech's levosimendan program.

At post $1.95Now $1.90-2.8% since postedas of Oct 1, 12:31 PM ET

1d-4.6%

3d-4.6%

1w-4.6%

1m-4.1%

3m—

6m—

1y—

original post →

$TENXr/pennystocksBullishbullish

u/Da1lyGa1ns · 46d ago3 prior · awaiting results

$TENX To present at Cantor Global Healthcare Conference 9/9/26 @ 8:35 am ET.

Tenax Therapeutics presents at Cantor Global Healthcare Conference on Sept 9, 2026, with price targets ranging $4-36 one year out. At under $2, the stock offers strong risk/reward with heavy institutional ownership before the catalyst event.

At post $1.94Now $1.90-2.3% since postedas of Oct 1, 12:31 PM ET

1d—

3d—

1w-4.1%

1m+2.1%

3m—

6m—

1y—

original post →

$TENXr/pennystocksBullishbullish

u/Da1lyGa1ns · 47d ago3 prior · awaiting results

$TENX Institutional Buyer 9/02/26!

A 10% institutional owner added 770k shares ($1.38M) ahead of Tenax's upcoming Cantor Global Healthcare Conference presentation, signaling strong insider confidence. The stock spiked to $2.05 after-hours on this news and the author expects a swift recovery from the $1.93 close.

At post $1.85Now $1.90+2.4% since postedas of Oct 1, 12:31 PM ET

1d-3.8%

3d+4.9%

1w+15.1%

1m+7.0%

3m—

6m—

1y—

original post →

$TENXr/pennystocksBullishbullish

u/Da1lyGa1ns · 48d ago3 prior · awaiting results

$TENX Recent Insider Buys!

TENX is undervalued trading at $1.81 with $200M+ cash against a $68M market cap. Insider buying (ADAR1 Capital loaded 1M+ shares) and an upcoming CEO conference presentation are expected catalysts for share price appreciation.

At post $1.80Now $1.90+5.3% since postedas of Oct 1, 12:31 PM ET

1d+2.8%

3d+7.8%

1w+10.0%

1m+7.2%

3m—

6m—

1y—

original post →

$TENXr/pennystocksDDbullish

u/Joehax00 · 106d ago3 prior · 0% at 3mo

TENX: Tenax Therapeutics. Fully-enrolled Phase 3. Results due August. $119M cash, no debt. Another binary biotech play (kinda)

Tenax Therapeutics is a well-funded biotech play on levosimendan (LEVEL Phase 3) for PH-HFpEF, an untreated, no-competitor indication. The fully-enrolled, well-powered trial is expected to report topline results in August 2026, with 40-60% approval odds at this stage—better odds than typical biotech lottery tickets. A positive readout would likely re-rate the stock substantially as the first-to-market option in a common condition with zero approved alternatives.

At post $16.26Now $1.90-88.3% since postedas of Oct 1, 12:31 PM ET

1d—

3d+9.0%

1w+7.9%

1m-15.0%

3m-87.8%

6m—

1y—

original post →

End of results.